Zynlonta

Zynlonta (loncastuximab tesirine) is an FDA-approved prescription therapy for relapsed or refractory large B-cell lymphoma. Administered intravenously, it targets CD19-positive cancer cells. This targeted treatment is designed for patients who have not responded to prior therapies. Always consult a healthcare provider for suitability.

Zynlonta is used to treat relapsed or refractory large B-cell lymphoma in adults who have received at least two prior systemic therapies. It is indicated specifically for diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. This medication targets CD19, a protein found on certain cancer cells, helping to slow disease progression. It is not a first-line treatment and is reserved for patients who have exhausted other options.

Patients receiving Zynlonta may experience effects related to its action on cancer cells, such as changes in blood cell counts or liver function. Common effects can include fatigue, nausea, or swelling in the limbs. Some individuals may notice skin reactions or changes in appetite. These effects vary by patient and should be monitored by a healthcare professional.

Zynlonta is administered under medical supervision due to its potent effects. Patients should inform their doctor of all medications, including over-the-counter and supplements, before starting treatment. Regular blood tests are typically required to monitor for potential complications. Avoiding live vaccines during treatment may be recommended.

Zynlonta may interact with other drugs that affect liver enzymes, such as CYP3A inhibitors or inducers, which can alter its effectiveness. Combining it with strong immunosuppressants could increase infection risk. Alcohol and certain herbal supplements may also interact unpredictably. Always disclose all medications to your healthcare provider.